These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25366268)

  • 1. Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase.
    van Ingen IL; Lamers-Karnebeek F; Jansen TL
    Expert Opin Biol Ther; 2014 Dec; 14(12):1761-7. PubMed ID: 25366268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
    Kavanaugh A; Lee SJ; Curtis JR; Greenberg JD; Kremer JM; Soto L; Etzel CJ; Cox V; Yoshida K; Reed GW; Solomon DH
    Ann Rheum Dis; 2015 Jun; 74(6):1150-5. PubMed ID: 25471471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of add-on tacrolimus on methotrexate to maintain clinical remission after rediscontinuation of a tumor necrosis factor inhibitor in rheumatoid arthritis patients who relapsed shortly after discontinuation of the same tumor necrosis factor inhibitor due to clinical remission.
    Naniwa T; Iwagaitsu S; Kajiura M
    Mod Rheumatol; 2017 Jan; 27(1):29-34. PubMed ID: 27143107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
    Tanaka Y; Hirata S
    Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
    Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Kalstad S; Kaufmann C; Rødevand E; Kvien TK
    Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review.
    Ward MM; Madanchi N; Yazdanyar A; Shah NR; Constantinescu F
    Arthritis Res Ther; 2023 Nov; 25(1):222. PubMed ID: 37986101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors.
    Lamers-Karnebeek FB; Luime JJ; Ten Cate DF; Teerenstra S; Swen NWAA; Gerards AH; Hendrikx J; van Rooyen EM; Voorneman R; Haagsma C; Basoski N; de Jager M; Ghiti Moghadam M; Efde MN; Goekoop-Ruiterman YPM; van Riel PLCM; Jacobs JWG; Jansen TL
    Rheumatology (Oxford); 2017 Sep; 56(9):1560-1565. PubMed ID: 28595367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.
    Ghiti Moghadam M; Vonkeman HE; Ten Klooster PM; Tekstra J; van Schaardenburg D; Starmans-Kool M; Brouwer E; Bos R; Lems WF; Colin EM; Allaart CF; Meek IL; Landewé R; Bernelot Moens HJ; van Riel PL; van de Laar MA; Jansen TL;
    Arthritis Rheumatol; 2016 Aug; 68(8):1810-7. PubMed ID: 26866428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis.
    Tanaka Y
    Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii15-ii22. PubMed ID: 27856656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M; Kaneko Y; Kondo H; Takeuchi T
    Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.
    Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Lexberg ÅS; Madland TM; Fremstad H; Høili CA; Bakland G; Spada C; Haukeland H; Hansen IM; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
    Ann Rheum Dis; 2023 Nov; 82(11):1394-1403. PubMed ID: 37607809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful cessation of tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients and potential predictors for early flare: An observational study in routine clinical care.
    Naniwa T; Iwagaitsu S; Kajiura M
    Mod Rheumatol; 2020 Nov; 30(6):948-958. PubMed ID: 31814481
    [No Abstract]   [Full Text] [Related]  

  • 14. Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis.
    Ogawa Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Yabe Y; Oguchi T; Fujibayashi T; Takagi H; Hanabayashi M; Funahashi K; Hayashi M; Tsuboi S; Asai S; Asai N; Matsumoto T; Sobue Y; Ishiguro N; Kojima T
    Clin Rheumatol; 2019 Oct; 38(10):2757-2763. PubMed ID: 31179526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry.
    Manders SH; Kievit W; Jansen TL; Stolk JN; Visser H; Schilder AM; Vonkeman HE; Adang E; van de Laar MA; van Riel PL
    J Rheumatol; 2016 Oct; 43(10):1787-1794. PubMed ID: 27481900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
    Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
    Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does a family history of RA influence the clinical presentation and treatment response in RA?
    Frisell T; Saevarsdottir S; Askling J
    Ann Rheum Dis; 2016 Jun; 75(6):1120-5. PubMed ID: 26091906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?
    Ibrahim F; Lorente-Cánovas B; Doré CJ; Bosworth A; Ma MH; Galloway JB; Cope AP; Pande I; Walker D; Scott DL
    Rheumatology (Oxford); 2017 Nov; 56(11):2004-2014. PubMed ID: 28968858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from TNFα inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFα inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial.
    Jung SY; Koh JH; Kim KJ; Park YW; Yang HI; Choi SJ; Lee J; Choi CB; Kim WU
    Arthritis Res Ther; 2021 Jul; 23(1):182. PubMed ID: 34233727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients.
    van den Brandt S; Zbinden A; Baeten D; Villiger PM; Østensen M; Förger F
    Arthritis Res Ther; 2017 Mar; 19(1):64. PubMed ID: 28320445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.